Costs of Outpatient Anticoagulant Treatment in Patients with Cerebral and Peripheral Arterial Occlusive Disease

Summary

Background and objective: Knowledge of the costs of oral anticoagulant (AC) treatment may be relevant for resource allocation. Also, the incremental costs may be compared with other treatments for health care policy decisions. In this report, we have assessed actual costs of anticoagulant therapy in anticoagulation clinics (AC-clinic) in three different settings in the Netherlands. Methods: Costs of anticoagulant drug supply and costs as a result of INR-adjustment procedures were estimated. We compared the total costs of treatment in patients treated after minor cerebral ischaemia in the Stroke Prevention in Reversible Ischemia Trial (SPIRIT) and in patients treated because of peripheral arterial occlusive disease in the Dutch Bypass Oral anticoagulants or Aspirin Trial (BOA). Results: Costs of monitoring ranged between Euro 6.44 and Euro 9.87 per visit for monitoring at the AC-clinic and at home, respectively. The annual costs of administering anticoagulant drugs ranged between Euro 83 (phenprocoumon) and 107 (acenocoumarol). Variation in the overall actual annual costs of AC treatment was caused by the number of monitoring visits, the distribution of home and clinic visits and, to a lesser extent, the medication used. Annual costs of AC therapy for patients in SPIRIT was Euro 239 and for patients in BOA Euro 312. Overall costs of anticoagulant therapy were about 3 to 4-fold higher than standard treatment with aspirin. Conclusions: Although the actual costs of anticoagulant therapy may be substantially higher than that of other antithrombotic therapies, its cost-effectiveness depends highly on efficacy.

Writing Committee: A. Algra MD, E. Buskens MD, J. W. Gorter MD, J. B. Oostenbrink MSc, M. J. D. Tangelder MD.

Extended writing committee: All above authors plus: B. C. Eikelboom MD, B. A. van Hout PhD, J. van Gijn MD, L. J. Kappelle MD, P. J. Koudstaal MD, J. A. Lawson MD, J. de Vries-Goldschmeding, MD (on behalf of the Federatie van Nederlandse Trombosediensten), and the SPIRIT and Dutch BOA Study Groups.

Keywords

Oral anticoagulants - costs - the Netherlands - secondary prevention

^* A full list of participants is published as an appendix in Ann Neurol 1997; 42: 857-65.

^** A full list of participants is published as an appendix in Lancet 2000; 355: 346-51.

• References

• 1 EAFT (European Atrial Fibrillation Trial) Study Group. Secondary prevention in non-rheumatic atrial fibrillation after transient ischaemic attack or minor stroke. Lancet 1993; 342: 1255-62.
• 2 Stroke Prevention in Atrial Fibrillation Investigators. Adjusted-dose warfarin versus low-intensity, fixed-dose warfarin plus aspirin for high-risk patients with atrial fibrillation: Stroke Prevention in Atrial Fibrillation III randomised clinical trial. Lancet 1996; 348: 633-8.
• 3 Smith P, Arnesen H, Holme I. The effect of warfarin on mortality and reinfarction after myocardial infarction. N Engl J Med 1990; 323: 147-52.
• 4 The Sixty Plus Reinfarction Study Research Group. A double-blind trial to assess long-term oral anticoagulant therapy in elderly patients after myocardial infarction. Lancet 1980; ii: 989-94.
• 5 Anticoagulants in the Secondary Prevention of Events in Coronary Thrombosis (ASPECT) Research Group. Effect of long-term oral anticoagulant treatment on mortality and cardiovascular morbidity after myocardial infarction. Lancet 1994; 353: 499-503.
• 6 The EPSIM Research Group. A controlled comparison of aspirin and oral anticoagulants in prevention of death after myocardial infarction. N Engl J Med 1982; 307: 701-8.
• 7 Cannegieter SC, Rosendaal FR, Wintzen AR, van der Meer FJM, Vandenbroucke JP, Briët E. Optimal oral anticoagulant therapy in patients with mechanical heart valves. N Engl J Med 1995; 333: 11-7.
• 8 Drummond MF, Stoddart GL, Torrance GW. ed. Methods for economic evaluation of health care programs. Oxford: Oxford Medical Publications; 1995
• 9 Algra A, Van Gijn J, Koudstaal PJ. Secondary prevention after cerebral ischaemia of presumed arterial origin: is aspirin still the touchstone?. J Neurol Neurosurg Psychiatry 1999; 66: 557-9.
• 10 van den Besselaar AM, van der Meer FJ, Gerrits-Drabbe CW. Therapeutic control of oral anticoagulant treatment in The Netherlands. Am J Clin Pathol 1988; 90: 685-90.
• 11 van Bergen PF, Jonker JJ, van Hout BA. et al. Costs and effects of longterm oral anticoagulant treatment after myocardial infarction. JAMA 1995; 273: 925-8.
• 12 Gustafsson C, Asplund K, Britton M, Norrving B, Olsson B, Marke LA. Cost effectiveness of primary stroke prevention in atrial fibrillation: Swedish national perspective. BMJ 1992; 305: 1457-60.
• 13 Gage BF, Cardinalli AB, Albers GW, Owens DK. Cost-effectiveness of warfarin and aspirin for prophylaxis of stroke in patients with nonvalvular atrial fibrillation. JAMA 1995; 274: 1839-45.
• 14 Gianetti J, Gensini G, De Caterina R. A cost-effectiveness analysis of aspirin versus oral anticoagulants after acute myocardial infarction in Italy – equivalence of costs as a possible case for oral anticoagulants. Thromb Haemost 1998; 80: 887-93.
• 15 The Stroke Prevention In Reversible Ischemia Trial (SPIRIT) Study Group. A randomized trial of anticoagulants versus aspirin after cerebral ischemia of presumed arterial origin. Ann Neurol 1997; 42: 857-65.
• 16 Dutch Bypass Oral Anticoagulants or Aspirin (BOA) Study Group. Efficacy of oral anticoagulants compared with aspirin after infrainguinal bypass surgery (The Dutch Bypass Oral Anticoagulant or Aspirin Study): a randomised trial. Lancet 2000; 355: 346-51.
• 17 van Swieten JC, Koudstaal PJ, Visser MC, Schouten HJ, van Gijn J. Interobserver agreement for the assessment of handicap in stroke patients. Stroke 1988; 19: 604-7.
• 18 The National Health Insurance Council. Farmacotherapeutisch compas. The Netherlands: 1996. and 1999
• 19 Cairns JA, Markham BA. Economics and efficacy in choosing oral anticoagulants or aspirin after myocardial infarction. JAMA 1995; 273: 965-7.
• 20 Goeree R, Gafni A, Hannah M, Myhr T, Blackhouse G. Hospital selection for unit cost estimates in multicentre economic evaluations; does the choice of hospitals make a difference. Pharmacoeconomics 1999; 15: 561-72.
• 21 Bergman L, Meulen JHP van der, Limburg M, Dik J, Habbema F. Costs of medical care after first-ever stroke in the Netherlands. Stroke 1995; 26: 1830-6.
• 22 Drummond MF, Bloom BS, Carrin G, Hillman AL, Hutchings HC, Knill-Jones RP, de Pouvourville G, Torfs K. Issues in the cross-national assessment of health technology. International Journal of Technology Assessment In Health Care 1992; 8: 671-82.